<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313155</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-850/CPH-002</org_study_id>
    <secondary_id>U1111-1164-1969</secondary_id>
    <secondary_id>JapicCTI-142724</secondary_id>
    <nct_id>NCT02313155</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults</brief_title>
  <official_title>A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of a single
      subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in
      healthy Japanese adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-850. This drug is being tested to evaluate
      the safety and immunogenicity of a single subcutaneous injection as compared to a single,
      intramuscular injection.

      A total of 110 healthy participants (55 per group) will take part in this study.

      Each participant will be randomly (like flipping a coin) assigned to receive one of the
      following :

        -  A single injection of TAK-850, subcutaneously , or

        -  A single injection of TAK-850, intramuscularly.

      Participants will make up to 3 visits to the study site. Total duration of this study is 22
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>Up to 21 days (Day 22) after vaccination</time_frame>
    <description>Number of participants with local reactions (injection site pain, injection site redness, injection site swelling, injection site induration, injection site tenderness, and injection site ecchymosis) and systemic events (pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, arthralgia, nausea and vomiting) were reported using an electronic diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 21 days (Day 22) after vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived Antigen) of &gt;=40.</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroprotection rate as measured by HI antibody titer (egg-derived antigen) was defined as percentage of participants with the HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroconversion rate as measured by the HI antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</measure>
    <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
    <description>GMFI in HI antibody titer (egg-derived antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values</measure>
    <time_frame>Baseline,up to 21 Days after drug administration (Day 22)</time_frame>
    <description>Laboratory values included hematology, biochemistry and urinalysis tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline, Day 22</time_frame>
    <description>Change from baseline in systolic and diastolic blood pressure was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse</measure>
    <time_frame>Baseline, Day 22</time_frame>
    <description>Change from baseline in pulse was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline, Day 22</time_frame>
    <description>Change from baseline in body temperature (oral) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) in HI Antibody Titer (Egg-derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>GMT in HI antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in SRH Antibody Titer (Egg-derived Antigen) of &gt;=25 mm^2</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroprotection rate as measured by SRH antibody titer (egg-derived antigen) was defined as percentage of participants with an SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroconversion rate as measured by the SRH antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in SRH Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</measure>
    <time_frame>Pre-vaccination, 21 Days after vaccination (Day 22)</time_frame>
    <description>GMFI in SRH antibody titer (egg-derived antigen) as compared to baseline pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT in SRH Antibody Titer (Egg-derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>GMT in SRH antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in HI Antibody Titer (Cell Derived Antigen) of &gt;=40</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroprotection rate as measured by HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with an HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in HI Antibody Titer (Cell Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroconversion rate as measured by the HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline HI &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in HI Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</measure>
    <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
    <description>GMFI in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT in HI Antibody Titer (Cell Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>GMT in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in SRH Antibody Titer (Cell Derived Antigen) of &gt;=25 mm^2</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroprotection rate as measured by SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with a SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in SRH Antibody Titer (Cell Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>Seroconversion rate as measured by the SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in SRH Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</measure>
    <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
    <description>GMFI in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT in SRH Antibody Titer (Cell Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after vaccination)</time_frame>
    <description>GMT in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Influenza Infection</condition>
  <arm_group>
    <arm_group_label>TAK-850 0.5 mL (subcutaneous)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection of TAK-850</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-850 0.5 mL (Intramuscular)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular injection of TAK-850</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous injection of TAK-850</intervention_name>
    <description>TAK-850 0.5 mL, Subcutaneous injection</description>
    <arm_group_label>TAK-850 0.5 mL (subcutaneous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular injection of TAK-850</intervention_name>
    <description>TAK-850 0.5 mL, Intramuscular injection</description>
    <arm_group_label>TAK-850 0.5 mL (Intramuscular)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator or subinvestigator, the participant is capable of
             understanding and complying with protocol requirements.

             2. The participant signs and dates a written, informed consent form prior to the
             initiation of any study procedures.

             3. The participant is a healthy Japanese adult male or female. 4. The participant is
             aged 20 to 49 years, inclusive, at the time of informed consent.

             5. The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m^2,
             inclusive, at the time of eligibility evaluation.

             6. If the participant is a female of childbearing potential who is sexually active
             with a nonsterilized male partner agrees to use routinely adequate contraception from
             signing of informed consent throughout the duration of the study.

        Exclusion Criteria:

          -  1. The participant has received any investigational compound within 4 months prior to
             the injection of study vaccine.

             2. The participant has been vaccinated with seasonal influenza vaccine within 6 months
             prior to the injection of study vaccine.

             3. The participant has a history of influenza infection within 6 months prior to the
             injection of study vaccine.

             4. The participant is a study site employee, an immediate family member of such an
             employee, or in a dependent relationship with a study site employee who is involved in
             the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under
             duress.

             5. The participant has uncontrolled, clinically significant manifestations of
             neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal,
             urologic, endocrine or other disorders, which may impact the ability of the
             participant to participate or potentially confound the study results.

             6. The participant has an oral temperature ≥37.5 °C prior to the injection of study
             vaccine on Day 1.

             7. The participant has any medically diagnosed or suspected immune deficient
             condition.

             8. The participant has an immune compromising condition or disease, or is currently
             undergoing a form of treatment or was undergoing a form of treatment that can be
             expected to influence immune response within 30 days prior to the injection of study
             vaccine. Such treatments include, but is not limited to, systemic or high dose inhaled
             corticosteroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent; the use of
             inhaled and nasal steroids that do not exceed this level will be permitted), radiation
             treatment or other immunosuppressive or cytotoxic drugs.

             9. The participant has received antipyretics within 4 hours prior to the injection of
             study vaccine.

             10. The participant has a history of Guillain-Barré Syndrome, demyelinating disorders
             (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis) or
             convulsions.

             11. The participant has a functional or surgical asplenia. 12. The participant has a
             rash, other dermatologic conditions or tattoos which may interfere with the evaluation
             of injection site reaction as determined by the investigator.

             13. The participant has a history of, or is infected with the Hepatitis B Virus
             (HBsAgs), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).

             14. The participant has a known hypersensitivity to any component of TAK-850. 15. The
             participant has a history of severe allergic reactions or anaphylaxis. 16. The
             participant has a history of drug abuse (defined as any illicit drug use) or a history
             of alcohol abuse within 1 year prior to the injection of study vaccine or is unwilling
             to agree to abstain from alcohol and drugs throughout the study.

             17. The participant has received any blood products (e.g. blood transfusion or
             immunoglobulin) within 90 days prior to the injection of study vaccine.

             18. The participant has received a live vaccine within 4 weeks (28 days) or an
             inactivated vaccine within 2 weeks (14 days) prior to the injection of study vaccine.

             19. If female, the participant is pregnant or lactating or intending to become
             pregnant before signing informed consent, during, or within 1 month after
             participating in this study; or intending to donate ova during such time period.

             20. The participant has donated whole blood ≥200 mL within 4 weeks (28 days), ≥400 mL
             within 12 weeks (84 days), ≥800 mL within 52 weeks (364 days), or blood components
             within 2 weeks (14 days) prior to the injection of study vaccine.

             21. The participant has abnormal laboratory values that suggest a clinically
             significant underlying disease at the assessment prior to the injection of study
             vaccine, or the participant has the following lab abnormalities: alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 3 times the
             upper limits of normal.

             22. In the opinion of the investigator or subinvestigator, the participant is unlikely
             to comply with protocol requirements or is considered ineligible for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior VP Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 13-December-2014 to 22-January-2015.</recruitment_details>
      <pre_assignment_details>Healthy adult participants were randomized to receive a single dose of 0.5 milliliter (mL) of TAK-850 in 1 of the 2 treatment groups: TAK-850 subcutaneous injection and TAK-850 intramuscular injection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-850 Subcutaneous Injection</title>
          <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
        </group>
        <group group_id="P2">
          <title>TAK-850 Intramuscular Injection</title>
          <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-850 Subcutaneous Injection</title>
          <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
        </group>
        <group group_id="B2">
          <title>TAK-850 Intramuscular Injection</title>
          <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.1" spread="3.50"/>
                    <measurement group_id="B2" value="25.1" spread="4.08"/>
                    <measurement group_id="B3" value="24.6" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.9" spread="8.83"/>
                    <measurement group_id="B2" value="165.5" spread="8.67"/>
                    <measurement group_id="B3" value="165.7" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.35" spread="7.325"/>
                    <measurement group_id="B2" value="58.19" spread="7.610"/>
                    <measurement group_id="B3" value="57.27" spread="7.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.41" spread="1.457"/>
                    <measurement group_id="B2" value="21.18" spread="1.561"/>
                    <measurement group_id="B3" value="20.79" spread="1.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Infection Within 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant had influenza infection in 1 year (yr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant didnot have influenza infection in 1yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemagglutination Inhibition (HI) (Egg-derived) - A/H1N1 at Day1 (Predose) Titer</title>
          <description>Number of participants with values of HI antibody titer for A/H1N1 strain pre-dose at Day 1 were reported. Influenza A/Hemagglutinin Type 1 and Neuraminidase Type 1 (A/H1N1). Greater than or equal to (&gt;=). Less than or equal to (&lt;=).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=Minimum (Min) to &lt;40 titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 to &lt;=Maximum (Max) titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HI(Egg-derived) - A/H3N2 at Day1(Predose) Titer</title>
          <description>Number of participants with values of HI antibody titer for A/H3N2 strain pre-dose at Day 1 were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=Min to less than (&lt;) 40 titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 to &lt;=Max titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HI(Egg-derived) - Influenza B(B) at Day1(Predose) Titer</title>
          <description>Number of participants with values of HI antibody titer for B strain pre-dose at Day 1 were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=Min to &lt; 40 titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 to &lt;=Max titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Number of participants with local reactions (injection site pain, injection site redness, injection site swelling, injection site induration, injection site tenderness, and injection site ecchymosis) and systemic events (pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, arthralgia, nausea and vomiting) were reported using an electronic diary.</description>
        <time_frame>Up to 21 days (Day 22) after vaccination</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Number of participants with local reactions (injection site pain, injection site redness, injection site swelling, injection site induration, injection site tenderness, and injection site ecchymosis) and systemic events (pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, arthralgia, nausea and vomiting) were reported using an electronic diary.</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweaty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Up to 21 days (Day 22) after vaccination</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived Antigen) of &gt;=40.</title>
        <description>Seroprotection rate as measured by HI antibody titer (egg-derived antigen) was defined as percentage of participants with the HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived Antigen) of &gt;=40.</title>
          <description>Seroprotection rate as measured by HI antibody titer (egg-derived antigen) was defined as percentage of participants with the HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="67.027" upper_limit="89.570"/>
                    <measurement group_id="O2" value="88.9" lower_limit="77.369" upper_limit="95.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" lower_limit="35.354" upper_limit="62.929"/>
                    <measurement group_id="O2" value="70.4" lower_limit="56.391" upper_limit="82.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="75.520" upper_limit="94.726"/>
                    <measurement group_id="O2" value="90.7" lower_limit="79.700" upper_limit="96.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroconversion rate as measured by the HI antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroconversion rate as measured by the HI antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                    <measurement group_id="O2" value="64.8" lower_limit="50.624" upper_limit="77.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="22.237" upper_limit="48.581"/>
                    <measurement group_id="O2" value="50.0" lower_limit="36.081" upper_limit="63.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="22.237" upper_limit="48.581"/>
                    <measurement group_id="O2" value="46.3" lower_limit="32.622" upper_limit="60.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H1N1 Strain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.858</ci_lower_limit>
            <ci_upper_limit>11.592</ci_upper_limit>
            <estimate_desc>Seroconversion rate difference between treatment groups was obtained by subtracting the value of TAK-850 I.M. from TAK-850 S.C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H3N2 Strain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-15.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.779</ci_lower_limit>
            <ci_upper_limit>2.870</ci_upper_limit>
            <estimate_desc>Seroconversion rate difference between treatment groups was obtained by subtracting the value of TAK-850 I.M. from TAK-850 S.C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B Strain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.048</ci_lower_limit>
            <ci_upper_limit>6.547</ci_upper_limit>
            <estimate_desc>Seroconversion rate difference between treatment groups was obtained by subtracting the value of TAK-850 I.M. from TAK-850 S.C.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
        <description>GMFI in HI antibody titer (egg-derived antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
        <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
          <description>GMFI in HI antibody titer (egg-derived antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" lower_limit="5.939" upper_limit="17.616"/>
                    <measurement group_id="O2" value="15.54" lower_limit="8.922" upper_limit="27.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.003" upper_limit="4.530"/>
                    <measurement group_id="O2" value="4.40" lower_limit="2.898" upper_limit="6.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" lower_limit="2.632" upper_limit="5.192"/>
                    <measurement group_id="O2" value="4.13" lower_limit="2.886" upper_limit="5.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values</title>
        <description>Laboratory values included hematology, biochemistry and urinalysis tests.</description>
        <time_frame>Baseline,up to 21 Days after drug administration (Day 22)</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values</title>
          <description>Laboratory values included hematology, biochemistry and urinalysis tests.</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure</title>
        <description>Change from baseline in systolic and diastolic blood pressure was reported</description>
        <time_frame>Baseline, Day 22</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure</title>
          <description>Change from baseline in systolic and diastolic blood pressure was reported</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>millimeter mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.3" spread="11.36"/>
                    <measurement group_id="O2" value="112.2" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure: Change at Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="9.78"/>
                    <measurement group_id="O2" value="-0.9" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" spread="7.50"/>
                    <measurement group_id="O2" value="66.3" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure: Change at Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.47"/>
                    <measurement group_id="O2" value="0.4" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse</title>
        <description>Change from baseline in pulse was reported.</description>
        <time_frame>Baseline, Day 22</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse</title>
          <description>Change from baseline in pulse was reported.</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="11.69"/>
                    <measurement group_id="O2" value="72.9" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse: Change at Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="11.35"/>
                    <measurement group_id="O2" value="-2.0" spread="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Temperature</title>
        <description>Change from baseline in body temperature (oral) was reported.</description>
        <time_frame>Baseline, Day 22</time_frame>
        <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature</title>
          <description>Change from baseline in body temperature (oral) was reported.</description>
          <population>Safety analysis set was defined as all participants who received vaccination with the study drug.</population>
          <units>degree celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.71" spread="0.305"/>
                    <measurement group_id="O2" value="36.72" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature: Change at Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.357"/>
                    <measurement group_id="O2" value="-0.20" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) in HI Antibody Titer (Egg-derived Antigen)</title>
        <description>GMT in HI antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) in HI Antibody Titer (Egg-derived Antigen)</title>
          <description>GMT in HI antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.30" lower_limit="87.531" upper_limit="234.589"/>
                    <measurement group_id="O2" value="237.43" lower_limit="156.037" upper_limit="361.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.91" lower_limit="14.256" upper_limit="33.683"/>
                    <measurement group_id="O2" value="51.21" lower_limit="32.446" upper_limit="80.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.56" lower_limit="59.943" upper_limit="113.715"/>
                    <measurement group_id="O2" value="107.13" lower_limit="78.013" upper_limit="147.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Egg-derived Antigen) of &gt;=25 mm^2</title>
        <description>Seroprotection rate as measured by SRH antibody titer (egg-derived antigen) was defined as percentage of participants with an SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Egg-derived Antigen) of &gt;=25 mm^2</title>
          <description>Seroprotection rate as measured by SRH antibody titer (egg-derived antigen) was defined as percentage of participants with an SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.513" upper_limit="100.000"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="53.293" upper_limit="79.319"/>
                    <measurement group_id="O2" value="75.9" lower_limit="62.359" upper_limit="86.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.513" upper_limit="100.000"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroconversion rate as measured by the SRH antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroconversion rate as measured by the SRH antibody titer (egg-derived antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                    <measurement group_id="O2" value="61.1" lower_limit="46.879" upper_limit="74.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="28.655" upper_limit="55.894"/>
                    <measurement group_id="O2" value="51.9" lower_limit="37.837" upper_limit="65.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="25.409" upper_limit="52.274"/>
                    <measurement group_id="O2" value="46.3" lower_limit="32.622" upper_limit="60.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in SRH Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
        <description>GMFI in SRH antibody titer (egg-derived antigen) as compared to baseline pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
        <time_frame>Pre-vaccination, 21 Days after vaccination (Day 22)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in SRH Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
          <description>GMFI in SRH antibody titer (egg-derived antigen) as compared to baseline pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5435" lower_limit="1.98252" upper_limit="3.26315"/>
                    <measurement group_id="O2" value="2.4169" lower_limit="1.87743" upper_limit="3.11144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7666" lower_limit="1.46398" upper_limit="2.13181"/>
                    <measurement group_id="O2" value="2.3687" lower_limit="1.86326" upper_limit="3.01124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5867" lower_limit="1.37637" upper_limit="1.82926"/>
                    <measurement group_id="O2" value="1.6380" lower_limit="1.42438" upper_limit="1.88370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT in SRH Antibody Titer (Egg-derived Antigen)</title>
        <description>GMT in SRH antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT in SRH Antibody Titer (Egg-derived Antigen)</title>
          <description>GMT in SRH antibody titer (egg-derived antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5840" lower_limit="69.35268" upper_limit="82.37530"/>
                    <measurement group_id="O2" value="82.4482" lower_limit="77.42068" upper_limit="87.80227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9569" lower_limit="23.40813" upper_limit="35.82096"/>
                    <measurement group_id="O2" value="34.0601" lower_limit="27.64669" upper_limit="41.96127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5747" lower_limit="67.07223" upper_limit="74.26000"/>
                    <measurement group_id="O2" value="73.2954" lower_limit="69.23834" upper_limit="77.59029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Cell Derived Antigen) of &gt;=40</title>
        <description>Seroprotection rate as measured by HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with an HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Cell Derived Antigen) of &gt;=40</title>
          <description>Seroprotection rate as measured by HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with an HI antibody titer of &gt;=40 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="28.655" upper_limit="55.894"/>
                    <measurement group_id="O2" value="46.3" lower_limit="32.622" upper_limit="60.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="28.655" upper_limit="55.894"/>
                    <measurement group_id="O2" value="55.6" lower_limit="41.400" upper_limit="69.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="45.907" upper_limit="72.977"/>
                    <measurement group_id="O2" value="72.2" lower_limit="58.356" upper_limit="83.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="82.413" upper_limit="97.983"/>
                    <measurement group_id="O2" value="98.1" lower_limit="90.108" upper_limit="99.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="87.474" upper_limit="99.557"/>
                    <measurement group_id="O2" value="96.3" lower_limit="87.253" upper_limit="99.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="87.474" upper_limit="99.557"/>
                    <measurement group_id="O2" value="94.4" lower_limit="84.611" upper_limit="98.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="80.046" upper_limit="96.982"/>
                    <measurement group_id="O2" value="98.1" lower_limit="90.108" upper_limit="99.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="82.413" upper_limit="97.983"/>
                    <measurement group_id="O2" value="92.6" lower_limit="82.107" upper_limit="97.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.281" upper_limit="99.954"/>
                    <measurement group_id="O2" value="94.4" lower_limit="84.611" upper_limit="98.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Cell Derived Antigen)</title>
        <description>Seroconversion rate as measured by the HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline HI &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Cell Derived Antigen)</title>
          <description>Seroconversion rate as measured by the HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 4-fold increase from the baseline HI antibody titer (baseline &gt;=10) or achieving an HI antibody titer of &gt;=40 (baseline HI &lt;10) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="28.655" upper_limit="55.894"/>
                    <measurement group_id="O2" value="42.6" lower_limit="29.235" upper_limit="56.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="23.814" upper_limit="50.437"/>
                    <measurement group_id="O2" value="50.0" lower_limit="36.081" upper_limit="63.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="22.237" upper_limit="48.581"/>
                    <measurement group_id="O2" value="48.1" lower_limit="34.343" upper_limit="62.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="40.554" upper_limit="68.030"/>
                    <measurement group_id="O2" value="70.4" lower_limit="56.391" upper_limit="82.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="27.023" upper_limit="54.093"/>
                    <measurement group_id="O2" value="50.0" lower_limit="36.081" upper_limit="63.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="20.681" upper_limit="46.707"/>
                    <measurement group_id="O2" value="38.9" lower_limit="25.920" upper_limit="53.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="31.970" upper_limit="59.446"/>
                    <measurement group_id="O2" value="61.1" lower_limit="46.879" upper_limit="74.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="33.653" upper_limit="61.196"/>
                    <measurement group_id="O2" value="57.4" lower_limit="43.208" upper_limit="70.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="20.681" upper_limit="46.707"/>
                    <measurement group_id="O2" value="33.3" lower_limit="21.092" upper_limit="47.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in HI Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
        <description>GMFI in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
        <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in HI Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
          <description>GMFI in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="2.101" upper_limit="4.570"/>
                    <measurement group_id="O2" value="3.51" lower_limit="2.311" upper_limit="5.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="1.872" upper_limit="3.791"/>
                    <measurement group_id="O2" value="4.17" lower_limit="2.792" upper_limit="6.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.069" upper_limit="3.891"/>
                    <measurement group_id="O2" value="3.74" lower_limit="2.666" upper_limit="5.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.95" lower_limit="5.012" upper_limit="12.609"/>
                    <measurement group_id="O2" value="12.70" lower_limit="7.823" upper_limit="20.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="2.684" upper_limit="5.812"/>
                    <measurement group_id="O2" value="5.88" lower_limit="3.835" upper_limit="9.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.336" upper_limit="4.351"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.717" upper_limit="4.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" lower_limit="3.767" upper_limit="9.396"/>
                    <measurement group_id="O2" value="9.12" lower_limit="5.740" upper_limit="14.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" lower_limit="3.609" upper_limit="8.431"/>
                    <measurement group_id="O2" value="8.10" lower_limit="4.931" upper_limit="13.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="2.516" upper_limit="5.364"/>
                    <measurement group_id="O2" value="3.45" lower_limit="2.483" upper_limit="4.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT in HI Antibody Titer (Cell Derived Antigen)</title>
        <description>GMT in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT in HI Antibody Titer (Cell Derived Antigen)</title>
          <description>GMT in HI antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.52" lower_limit="11.513" upper_limit="26.666"/>
                    <measurement group_id="O2" value="20.72" lower_limit="13.374" upper_limit="32.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.63" lower_limit="11.714" upper_limit="26.540"/>
                    <measurement group_id="O2" value="32.05" lower_limit="20.018" upper_limit="51.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.24" lower_limit="18.672" upper_limit="39.731"/>
                    <measurement group_id="O2" value="37.40" lower_limit="26.335" upper_limit="53.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.83" lower_limit="192.610" upper_limit="397.866"/>
                    <measurement group_id="O2" value="424.41" lower_limit="317.572" upper_limit="567.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.48" lower_limit="154.101" upper_limit="282.045"/>
                    <measurement group_id="O2" value="320.00" lower_limit="225.694" upper_limit="453.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.29" lower_limit="113.528" upper_limit="170.887"/>
                    <measurement group_id="O2" value="168.43" lower_limit="125.641" upper_limit="225.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.47" lower_limit="171.653" upper_limit="386.187"/>
                    <measurement group_id="O2" value="381.77" lower_limit="289.028" upper_limit="504.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.89" lower_limit="132.545" upper_limit="266.336"/>
                    <measurement group_id="O2" value="309.89" lower_limit="208.367" upper_limit="460.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.89" lower_limit="151.967" upper_limit="232.298"/>
                    <measurement group_id="O2" value="210.85" lower_limit="155.714" upper_limit="285.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Cell Derived Antigen) of &gt;=25 mm^2</title>
        <description>Seroprotection rate as measured by SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with a SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Cell Derived Antigen) of &gt;=25 mm^2</title>
          <description>Seroprotection rate as measured by SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants with a SRH antibody titer of &gt;=25 mm^2 for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="62.980" upper_limit="86.772"/>
                    <measurement group_id="O2" value="70.4" lower_limit="56.391" upper_limit="82.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.281" upper_limit="99.954"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.281" upper_limit="99.954"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.281" upper_limit="99.954"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93.513" upper_limit="100.000"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93.513" upper_limit="100.000"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="77.753" upper_limit="95.890"/>
                    <measurement group_id="O2" value="94.4" lower_limit="84.611" upper_limit="98.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="84.877" upper_limit="98.861"/>
                    <measurement group_id="O2" value="98.1" lower_limit="90.108" upper_limit="99.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93.513" upper_limit="100.000"/>
                    <measurement group_id="O2" value="100" lower_limit="93.397" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Cell Derived Antigen)</title>
        <description>Seroconversion rate as measured by the SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Cell Derived Antigen)</title>
          <description>Seroconversion rate as measured by the SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) was defined as percentage of participants achieving a minimal 50% increase from the baseline SRH antibody titer (baseline &gt;4 mm^2) or achieving an SRH antibody titer of &gt;=25 mm^2 (baseline &lt;=4 mm^2) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain).</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="47.726" upper_limit="74.591"/>
                    <measurement group_id="O2" value="63.0" lower_limit="48.742" upper_limit="75.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="59.038" upper_limit="83.862"/>
                    <measurement group_id="O2" value="77.8" lower_limit="64.400" upper_limit="87.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="31.970" upper_limit="59.446"/>
                    <measurement group_id="O2" value="44.4" lower_limit="30.920" upper_limit="58.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="37.071" upper_limit="64.646"/>
                    <measurement group_id="O2" value="46.3" lower_limit="32.622" upper_limit="60.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="25.409" upper_limit="52.274"/>
                    <measurement group_id="O2" value="44.4" lower_limit="30.920" upper_limit="58.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="22.237" upper_limit="48.581"/>
                    <measurement group_id="O2" value="48.1" lower_limit="34.343" upper_limit="62.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                    <measurement group_id="O2" value="61.1" lower_limit="46.879" upper_limit="74.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="33.653" upper_limit="61.196"/>
                    <measurement group_id="O2" value="55.6" lower_limit="41.400" upper_limit="69.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="22.237" upper_limit="48.581"/>
                    <measurement group_id="O2" value="38.9" lower_limit="25.920" upper_limit="53.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in SRH Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
        <description>GMFI in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
        <time_frame>Pre-vaccination, 21 Days After vaccination (Day 22)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in SRH Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination</title>
          <description>GMFI in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) as compared to pre-vaccination was evaluated for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain). Geometric mean and CI were calculated for GMFIs.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8410" lower_limit="2.27071" upper_limit="3.55446"/>
                    <measurement group_id="O2" value="3.4599" lower_limit="2.68443" upper_limit="4.45933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2144" lower_limit="1.90391" upper_limit="2.57562"/>
                    <measurement group_id="O2" value="2.4938" lower_limit="2.09701" upper_limit="2.96573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7421" lower_limit="1.49521" upper_limit="2.02974"/>
                    <measurement group_id="O2" value="1.7632" lower_limit="1.51939" upper_limit="2.04622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4134" lower_limit="1.77374" upper_limit="3.28374"/>
                    <measurement group_id="O2" value="2.4059" lower_limit="1.77115" upper_limit="3.26809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0173" lower_limit="1.53910" upper_limit="2.64419"/>
                    <measurement group_id="O2" value="2.2430" lower_limit="1.69452" upper_limit="2.96898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7655" lower_limit="1.42885" upper_limit="2.18152"/>
                    <measurement group_id="O2" value="1.8173" lower_limit="1.49254" upper_limit="2.21278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6215" lower_limit="2.03478" upper_limit="3.37729"/>
                    <measurement group_id="O2" value="3.1694" lower_limit="2.38685" upper_limit="4.20840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6078" lower_limit="1.98732" upper_limit="3.42193"/>
                    <measurement group_id="O2" value="2.8178" lower_limit="2.10367" upper_limit="3.77438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6128" lower_limit="1.37610" upper_limit="1.89014"/>
                    <measurement group_id="O2" value="1.5651" lower_limit="1.35121" upper_limit="1.81284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT in SRH Antibody Titer (Cell Derived Antigen)</title>
        <description>GMT in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
        <time_frame>Day 22 (21 days after vaccination)</time_frame>
        <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 Subcutaneous Injection</title>
            <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 Intramuscular Injection</title>
            <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT in SRH Antibody Titer (Cell Derived Antigen)</title>
          <description>GMT in SRH antibody titer (vero antigen, live-vero antigen, and madin-darby canine kidney [MDCK] antigen) for each of the three influenza virus strains (A/H1N1 strain, A/H3N2 strain, and B strain) was computed along with 95% CI.</description>
          <population>Full analysis set was defined as participants who were randomized and received vaccination with the study drug.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2669" lower_limit="24.46183" upper_limit="35.01576"/>
                    <measurement group_id="O2" value="33.3318" lower_limit="27.94941" upper_limit="39.75064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3488" lower_limit="48.65362" upper_limit="58.49703"/>
                    <measurement group_id="O2" value="57.3376" lower_limit="52.02305" upper_limit="63.19507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4941" lower_limit="47.87718" upper_limit="55.38425"/>
                    <measurement group_id="O2" value="54.3183" lower_limit="50.64237" upper_limit="58.26095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3268" lower_limit="68.22339" upper_limit="87.64491"/>
                    <measurement group_id="O2" value="87.2200" lower_limit="82.62689" upper_limit="92.06834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9017" lower_limit="70.70835" upper_limit="81.47657"/>
                    <measurement group_id="O2" value="79.7297" lower_limit="73.82638" upper_limit="86.10500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live-Vero antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4468" lower_limit="73.26937" upper_limit="81.86249"/>
                    <measurement group_id="O2" value="82.3667" lower_limit="78.50179" upper_limit="86.42200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3793" lower_limit="36.13208" upper_limit="52.08009"/>
                    <measurement group_id="O2" value="51.8747" lower_limit="46.86724" upper_limit="57.41712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7714" lower_limit="45.49007" upper_limit="61.21810"/>
                    <measurement group_id="O2" value="60.2234" lower_limit="52.03699" upper_limit="69.69772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDCK antigen: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9627" lower_limit="79.99444" upper_limit="88.12783"/>
                    <measurement group_id="O2" value="87.5052" lower_limit="83.09898" upper_limit="92.14495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent AEs will be defined as any AEs, regardless of relationship to study drug, that occur or worsen after the dose of study drug and no more than 21 days after the study drug administration (up to Day 22).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-850 Subcutaneous Injection</title>
          <description>TAK-850 0.5 mL (15 microgram [mcg] of hemagglutinin [HA] per strain), injection, subcutaneous, once on Day 1 in a treatment period of 22 days.</description>
        </group>
        <group group_id="E2">
          <title>TAK-850 Intramuscular Injection</title>
          <description>TAK-850 0.5 mL (15 mcg of HA per strain), injection, intramuscular, once on Day 1 in a treatment period of 22 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

